Coverage window: June 4-11, 2026
This week is registry-heavy, but not slow. New records point to intranasal MSC exosomes for frontotemporal dementia, two MSC approaches in acute ischemic stroke, long-term follow-up for hESC-derived retinal cells, an active Parkinson cell-replacement study, an extracellular-vesicle secretome trial in Crohn's disease, and a GMP-grade UC-MSC spinal cord injury paper.
The common thread is practical: product identity, route, dose, endpoint, and follow-up. Those are the details that matter when results start appearing.
1. A frontotemporal dementia MSC-exosome trial is now registered
Full analysis: An Intranasal MSC-Exosome Trial Enters Frontotemporal Dementia
Primary source: https://clinicaltrials.gov/study/NCT07638813
ClinicalTrials.gov first posted NCT07638813 on June 10. The Ruijin Hospital study is listed as a Phase 1/2 trial of intranasal umbilical-cord MSC-derived exosomes in frontotemporal dementia.
The planned enrollment is 33. The record describes randomized triple-masked assignment, low-dose and high-dose exosome arms, and placebo. It also names both a clinical endpoint, change in CDR plus NACC FTLD score at 24 weeks, and safety/tolerability through the end of treatment.
The design is the item to notice: route, dose arms, masking, placebo, and a named FTD scale before results appear.
2. Two acute-stroke MSC studies put placebo-controlled designs on the table
Full analysis: Two Acute-Stroke MSC Trials Bring Placebo Control Into Focus
Primary sources:
Two acute ischemic stroke MSC studies appeared in the same week.
NCT07628933, first posted June 5, is a not-yet-recruiting Phase 1 study of umbilical-cord mesenchymal stromal cells from BOE Technology Group. It uses randomized placebo-controlled dose-escalation and multiple-dose phases.
NCT07635758, first posted June 9, is a recruiting Phase 1/2 study of human placenta-derived 3D MSCs from Chinese PLA General Hospital. It lists IV administration and a 90-day modified Rankin Scale 0-2 primary outcome.
Acute stroke is a difficult setting for cell therapy. Timing, baseline severity, spontaneous recovery, rehabilitation, and endpoint choice can all move the final read. Together, the records show how the sponsors plan to handle placebo, dose, route, and functional outcome.
3. Astellas keeps long-term hESC-RPE safety follow-up active
Primary source: https://clinicaltrials.gov/study/NCT03167203
Astellas Institute for Regenerative Medicine updated NCT03167203 on June 11. The record describes an enrolling-by-invitation long-term safety surveillance study for participants who previously received subretinal human embryonic stem-cell-derived retinal pigment epithelial cells in an AIRM-sponsored trial.
The safety follow-up runs up to 15 years and includes ophthalmologic, neurologic, infectious, hematologic, immune-mediated, cancer, cell-proliferation, ectopic-tissue, pregnancy, and mortality outcomes.
For replacement cell products, follow-up after the first trial is part of development. Delayed proliferation, ectopic tissue, immune events, and long monitoring all shape whether a product can move beyond a specialized early study.
4. UX-DA001 remains active in Parkinson's cell-replacement development
Primary source: https://clinicaltrials.gov/study/NCT06778265
NCT06778265 was updated on June 11. The Shanghai UniXell Biotechnology Phase 1 study of UX-DA001 in idiopathic Parkinson's disease is listed as active, not recruiting, with 12 estimated participants.
The registry describes UX-DA001 as human midbrain dopaminergic progenitor cells implanted into the bilateral putamina under stereotactic neurosurgery. Two dose levels are planned. Primary safety outcomes cover surgery/product-associated adverse events early and adverse events or serious adverse events through two years.
The update keeps an autologous iPSC-derived dopaminergic program visible in a field where allogeneic and autologous approaches are solving different problems. Manufacturing, immune management, timing, and scalability are all part of the Parkinson cell-replacement development picture.
5. Direct Biologics registers a Phase 2 MSC-EV study in Crohn's disease
Primary source: https://clinicaltrials.gov/study/NCT07625293
Direct Biologics' NCT07625293 was first posted June 4 as a not-yet-recruiting Phase 2 study of DB-3Q for medically refractory Crohn's disease.
The registry describes DB-3Q as a bone-marrow MSC-derived, extracellular-vesicle-enriched secretome product. The study lists placebo comparator, 36 estimated participants, and change from baseline in SES-CD at 12 weeks as the primary outcome.
Crohn's disease sits outside the CNS center of this newsletter, but DB-3Q is relevant to the broader MSC/extracellular-vesicle field. The endpoint is the reason to notice it: an endoscopic disease-severity score, not only symptom language.
6. GMP-grade UC-MSCs in a rat spinal cord injury model
Primary source: https://link.springer.com/article/10.1186/s12967-026-08373-x
A June 10 open-access Journal of Translational Medicine paper tested GMP-grade human umbilical-cord MSCs in a rat T10 spinal cord injury model.
The study used IV dosing on post-injury days 3 and 7, compared low and high cell doses, and reports that the high-dose group improved BBB locomotor scores from days 7 to 21, reduced lesion volume and inflammatory markers, and showed initial pulmonary cell accumulation followed by clearance within three days.
Why it matters: the design reads as a translational package: GMP-grade cells, low- and high-dose comparison, imaging, histology, immune profiling, cell tracking, and exosome RNA analysis in one spinal cord injury model.
7. A measles-vector iPSC reprogramming paper belongs on the manufacturing radar
Primary source: https://www.cell.com/molecular-therapy-family/advances/fulltext/S3117-387X%2826%2900058-3
Molecular Therapy Advances published a paper on a measles-virus-vector reprogramming platform for generating human iPSCs.
The abstract reports improved average reprogramming efficiency compared with the group's earlier system, rapid vector elimination at or before passage four, and differentiation capacity across lineages including neuronal progenitor cells.
This belongs in the manufacturing and starting-cell layer that replacement programs depend on. Reprogramming platforms deserve attention when they change efficiency, residual-vector behavior, or reproducibility, especially if the same platform later feeds a disease-specific product.